
- | Clene Nanomedicine
Clene, Inc. is making huge strides against MS, ALS, Parkinson’s Disease
Imagine a future where such diseases as Multiple Sclerosis, Lou Gehrig’s and Parkinson’s Disease can be controlled or stopped altogether.

- | Valneva
The Dark Horse of the Vaccine Race May Be This French Biotech
The company, Valneva SE, has a vaccine that could be more variant-proof, giving it an edge over other shots in what may be an annual campaign against a disease that’s already killed more than 3 million people. The first participant in its phase three trials will be dosed this week. If successful, that could lead to an approved shot in the fall.

- | OSE Immunotherapeutics
Preparing a Pandemic Plan for Whatever Comes Our Way Next
Which is why OSE Immunotherapeutics is developing a vaccine that aims to be pan-coronavirus. The formulation for CoVepiT, which focuses on inducing a lasting T cell immune response, is made up of 11 total viral targets. This way, even if one changes, there are still 10 other potentially valid targets.

- | Pyxis Oncology
Pyxis debuts next-gen cancer ADCs from under Pfizer’s wing
After raising a monster $152 million in a series B round last month, Pfizer darling Pyxis Oncology is ready to share more details about what it’ll be working on with all that cash.

- | Sio Gene Therapies
An experimental gene therapy was little Alissa’s only hope. Now, instead of certain death, she faces an uncertain future.
Thomas Feldborg and Daria Rokina set off nearly every afternoon to explore this city. They leave from their hotel in the Charlestown neighborhood, pushing their baby carriage, some days heading deep into downtown, others choosing a path along the Charles River.

- | Gain Therapeutics
Direct Listing vs. IPO
The company Richman leads, Gain Therapeutics, went public in March through an IPO. Regardless, he still thinks that going public through a SPAC is a trend that’s sustainable, even saying Gain Therapeutics considered it.

- | Vaxart
Had It Been Covid-19 Oral Pill, More Americans Would Have Opted For Vaccination: Poll
A third of those American adults now refusing to get vaccinated would get vaccinated if they could take a pill instead of getting the vaccine shot, according to a poll conducted by Quadrant Strategies and commissioned by biotechnology company Vaxart, Inc. A pill vaccine is expected to overcome vaccine resistance of millions of Americans.

- | ImmunityBio
Antibody Structure: All You Ever Wanted – and Needed – to Know
“Differences in heavy chain polypeptides allow these immunoglobulins to function in different types of immune responses and at particular stages of the immune response. The polypeptide protein sequences responsible for these differences are found primarily in the Fc fragment,” explained Dr. Patrick Soon-Shiong, world-class bioscientist and executive chairman of ImmunityBio